Answers are grounded in this paper and cite their sources.
ABSTRACT Introduction Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that specifically targets cancer cells. In NIR-PIT, antibody-photo-absorber-conjugates (APCs), specific for cancer antigens, target cancer cells. APCs that bind to antigens and are irradiated with NIR-light kill targeted cells. NIR-PIT has been clinically applied to head and neck squamous cell carcinoma in Japan, but not to pediatric cancers. Generally, neuroblastoma and osteosarcoma express GD2 antigen, making NIR-PIT that targets GD2 an additional treatment option. Methods Antihuman GD2 monoclonal antibody (clone 3F8) was conjugated with photo-absorber, IRDyeⓇ 700DX. A human neuroblastoma cell (SK-N-SH) was used for in vitro and in vivo experiments, whereas human osteosarcoma cells (NOS-10, MG-63) were utilized for in vitro experiments. Microscopy and flow cytometry was used to evaluate cell death after NIR-PIT, and longitudinal measurement of tumor size and histological observation were utilized to assess the effect of NIR-PIT on the xenograft model. Results EthD-1 staining after NIR-PIT confirmed the morphological changes (swelling and bleb formation) observed by microscopy and cell death. Flow cytometry verified the significant increase in dead cells after NIR-PIT. Tumor growth in the mice model was significantly inhibited at day 10 of the experiment and destroyed tumor tissue was histologically observed in the PIT-treated mice. Conclusion The efficacy of NIR-PIT with antiGD2 antibody for neuroblastoma and osteosarcoma was indicated. Additionally, NIR-PIT efficacy against neuroblastoma was indicated by the mice model in vivo. Therefore, further experiments and more effective protocols should be considered for clinical application.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: